in 1995, amylin pharmactietucals signed an agreement with johnson & johnson's lifescan division to further develop pramlintide. a phase ii study made public in january 1997 showed pramlintide was safe to mix with leading short-acting and intermediate-acting commercial insulin products, with preliminary results suggesting it might improve glucose control.